Genital Diseases, Female News - LARVOL Sigma

Genital Diseases, Female

Welcome, Profile Billing Logout

160 Mechanisms of Action

«1 2...99 100 101 102 103104105 106 107 108 109...110 111 »

|||||||||| Trial completion: Diamel in the Treatment of Polycystic Ovary Syndrome (clinicaltrials.gov) - May 1, 2012
P3, N=110, Completed, Sponsor: Catalysis SL
Active, not recruiting --> Completed

||||||||||  Follistim AQ Cartridge (follitropin beta) / Organon
New P2/3 trial:  Addition of Prednisolone and Heparin in Patients Undergoing IVF With Failed IVF Cycles (clinicaltrials.gov) -  Apr 30, 2012
P2/3, N=200, Recruiting,  Sponsor: National and Kapodistrian University of Athens

||||||||||  calcitriol (BPM 31543) / BPGbio
New P1 trial, Metastases:  Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for Advanced or Recurrent Disease (clinicaltrials.gov) -  Apr 29, 2012
P1, N=18, Recruiting,  Sponsor: Berg Pharma,LLC

|||||||||| Enrollment open: The Association of G9a Protein and the Outcome of Patients With Cervical Cancer (clinicaltrials.gov) - Apr 29, 2012
P=N/A, N=70, Recruiting, Sponsor: Far Eastern Memorial Hospital
Active, not recruiting --> Completed Not yet recruiting --> Recruiting

|||||||||| Trial termination: Racial Disparity in Endometrial Cancer (clinicaltrials.gov) - Apr 26, 2012
P=N/A, N=43, Terminated, Sponsor: James Graham Brown Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated; Funding and logistical difficuties resulted in the withdrawl of the study.

|||||||||| Enrollment change: Racial Disparity in Endometrial Cancer (clinicaltrials.gov) - Apr 26, 2012
P=N/A, N=43, Terminated, Sponsor: James Graham Brown Cancer Center
Active, not recruiting --> Terminated; Funding and logistical difficuties resulted in the withdrawl of the study. N=300 --> 43

||||||||||  Invanz (ertapenem) / Merck (MSD)
New P1 trial:  Pharmacokinetics and Safety of Ertapenem in the Postpartum Period (clinicaltrials.gov) -  Apr 26, 2012
P1, N=3, Terminated,  Sponsor: Daniel Benjamin

||||||||||  Leukine (sargramostim) / Partner Therap
Trial completion:  GM-CSF, Sargramostim in Women With Recurrent Ovarian Cancer (clinicaltrials.gov) -  Apr 26, 2012
P2, N=70, Completed,  Sponsor: Massachusetts General Hospital
N=300 --> 43 Active, not recruiting --> Completed

||||||||||  flutamide / Generic mfg.
Trial termination:  Effects of Flutamide on Insulin and Glucose Metabolism in Women With Polycystic Ovary Syndrome (clinicaltrials.gov) -  Apr 25, 2012
P=N/A, N=8, Terminated,  Sponsor: Virginia Commonwealth University
Active, not recruiting --> Completed Recruiting --> Terminated; Lack of recruitment

||||||||||  flutamide / Generic mfg.
Enrollment change:  Effects of Flutamide on Insulin and Glucose Metabolism in Women With Polycystic Ovary Syndrome (clinicaltrials.gov) -  Apr 25, 2012
P=N/A, N=8, Terminated,  Sponsor: Virginia Commonwealth University
Recruiting --> Terminated; Lack of recruitment N=66 --> 8

|||||||||| Enrollment open: Vulvar Contact Dermatitis Resulting From Urine Incontinence (clinicaltrials.gov) - Apr 25, 2012
P=N/A, N=400, Recruiting, Sponsor: Meir Medical Center
N=66 --> 8 Not yet recruiting --> Recruiting

|||||||||| Enrollment open: Postpartum Dyspareunia Resulting From Vaginal Atrophy (clinicaltrials.gov) - Apr 25, 2012
P=N/A, N=100, Recruiting, Sponsor: Meir Medical Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting

|||||||||| Trial completion: Efficacy and Safety, Long-Term Study of NPC-01 to Treat Dysmenorrhea Associated With Endometriosis (clinicaltrials.gov) - Apr 25, 2012
P3, N=148, Completed, Sponsor: Nobelpharma
Not yet recruiting --> Recruiting Active, not recruiting --> Completed

|||||||||| Trial completion: Insulin and Polycystic Ovary Syndrome (clinicaltrials.gov) - Apr 25, 2012
P=N/A, N=21, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Ophena (ospemifene) / Shionogi
New P3 trial:  Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus (clinicaltrials.gov) -  Apr 24, 2012
P3, N=301, Completed,  Sponsor: Shionogi

||||||||||  Ophena (ospemifene) / Shionogi
New P3 trial:  Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus (clinicaltrials.gov) -  Apr 24, 2012
P3, N=180, Completed,  Sponsor: Shionogi

||||||||||  pioglitazone / Generic mfg.
Trial withdrawal, Immunomodulating:  Endometriosis: Immunomodulation (clinicaltrials.gov) -  Apr 24, 2012
P2/3, N=0, Withdrawn,  Sponsor: University of Wisconsin, Madison
Active, not recruiting --> Completed Recruiting --> Withdrawn

||||||||||  pioglitazone / Generic mfg.
Enrollment change, Immunomodulating:  Endometriosis: Immunomodulation (clinicaltrials.gov) -  Apr 24, 2012
P2/3, N=0, Withdrawn,  Sponsor: University of Wisconsin, Madison
Recruiting --> Withdrawn N=140 --> 0

||||||||||  Camtobell (belotecan) / Equisnzaroo
Enrollment change:  Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix (clinicaltrials.gov) -  Apr 24, 2012
P2, N=16, Completed,  Sponsor: Sokbom Kang
N=140 --> 0 N=53 --> 16

||||||||||  celecoxib oral / Generic mfg.
Enrollment closed:  Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia (clinicaltrials.gov) -  Apr 24, 2012
P2, N=130, Active, not recruiting,  Sponsor: Gynecologic Oncology Group
N=53 --> 16 Recruiting --> Active, not recruiting

||||||||||  Camtobell (belotecan) / Equisnzaroo
Trial completion:  Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine Cervix (clinicaltrials.gov) -  Apr 24, 2012
P2, N=16, Completed,  Sponsor: Sokbom Kang
Recruiting --> Active, not recruiting Recruiting --> Completed

||||||||||  oxaliplatin / Generic mfg.
New P2 trial, Surgery:  IPHC in Patients With Platinum-sensitive Recurrent Ovarian Cancer (clinicaltrials.gov) -  Apr 23, 2012
P2, N=30, Completed,  Sponsor: Catholic University of the Sacred Heart

||||||||||  Young TIL / National Cancer Institute
New P2 trial, Metastases:  Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers (clinicaltrials.gov) -  Apr 23, 2012
P2, N=73, Recruiting,  Sponsor: National Cancer Institute (NCI)

||||||||||  cisplatin / Generic mfg., everolimus / Generic mfg.
Enrollment open, Metastases:  PHOENIX I: A Study of mTOR Inhibitor Everolimus (RAD001) in Association With Cisplatin and Radiotherapy for Locally Advanced Cervix Cancer (clinicaltrials.gov) -  Apr 23, 2012
P1, N=9, Recruiting,  Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Not yet recruiting --> Recruiting

||||||||||  clindamycin phosphate / Generic mfg.
New P4 trial:  TUPAC: Treatment Utility of Postpartum Antibiotics in Chorioamnionitis (clinicaltrials.gov) -  Apr 22, 2012
P4, N=238, Recruiting,  Sponsor: Washington University School of Medicine

||||||||||  ketoconazole / Generic mfg.
New P2 trial, Metastases:  GreKo: Ketoconazole as Inhibitor of the Enzyme CYP17 in Locally Advanced or Disseminated Granulosa Cell Tumour of Ovary (clinicaltrials.gov) -  Apr 22, 2012
P2, N=17, Recruiting,  Sponsor: Grupo Español de Tumores Huérfanos e Infrecuentes

||||||||||  celecoxib oral / Generic mfg.
Trial termination:  A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers (clinicaltrials.gov) -  Apr 21, 2012
P2, N=23, Terminated,  Sponsor: Mark H. Einstein
Not yet recruiting --> Recruiting Suspended --> Terminated; Due to reported toxicity of Celecoxib at high doses

||||||||||  ifosfamide / Generic mfg.
Enrollment change:  Adjuvant Radiation Therapy With Ifosfamide in Patients With Mixed Mesodermal Tumors of the Uterus (clinicaltrials.gov) -  Apr 21, 2012
P2, N=27, Completed,  Sponsor: Montefiore Medical Center
Suspended --> Terminated; Due to reported toxicity of Celecoxib at high doses N=18 --> 27

|||||||||| New P1 trial: Evaluation of the Zetiq Histological and Cytological Staining Technique for the Detection Cervical Cancer (clinicaltrials.gov) - Apr 21, 2012
P1, N=210, Completed, Sponsor: Meir Medical Center

||||||||||  ifosfamide / Generic mfg.
Trial completion:  Adjuvant Radiation Therapy With Ifosfamide in Patients With Mixed Mesodermal Tumors of the Uterus (clinicaltrials.gov) -  Apr 21, 2012
P2, N=27, Completed,  Sponsor: Montefiore Medical Center
N=18 --> 27 Active, not recruiting --> Completed

||||||||||  acyclovir / Generic mfg.
Enrollment change:  PK/GUD: GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women (clinicaltrials.gov) -  Apr 19, 2012
P=N/A, N=88, Completed,  Sponsor: University of Washington
Active, not recruiting --> Completed N=156 --> 88

||||||||||  Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
Enrollment change:  Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva (clinicaltrials.gov) -  Apr 19, 2012
P=N/A, N=8, Active, not recruiting,  Sponsor: Memorial Sloan-Kettering Cancer Center
N=156 --> 88 N=20 --> 8

|||||||||| HEOR: A Survivorship Care Plan for Gynaecological Cancer Patients (clinicaltrials.gov) - Apr 19, 2012
P=N/A, N=75, Recruiting, Sponsor: Royal Marsden NHS Foundation Trust

||||||||||  Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
Enrollment closed:  Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva (clinicaltrials.gov) -  Apr 19, 2012
P=N/A, N=8, Active, not recruiting,  Sponsor: Memorial Sloan-Kettering Cancer Center
N=20 --> 8 Recruiting --> Active, not recruiting

|||||||||| Trial termination: Improving the Pregnancy Rate With Endometrial Sampling Before Intrauterine Insemination (clinicaltrials.gov) - Apr 18, 2012
P=N/A, N=9, Terminated, Sponsor: McGill University Health Center
Recruiting --> Active, not recruiting Recruiting --> Terminated; Because very low number of patients were enrolled

||||||||||  nimodipine / Generic mfg.
Trial initiation date:  Use of a Calcium Channel Blocker to Prevent Premature Luteinizing Hormone Surges in Infertility Patients (clinicaltrials.gov) -  Apr 18, 2012
P2, N=90, Not yet recruiting,  Sponsor: Mount Sinai Hospital, Canada
Recruiting --> Terminated; Because very low number of patients were enrolled Initiation date: Mar 2012 --> Jul 2012

|||||||||| Enrollment change: Improving the Pregnancy Rate With Endometrial Sampling Before Intrauterine Insemination (clinicaltrials.gov) - Apr 18, 2012
P=N/A, N=9, Terminated, Sponsor: McGill University Health Center
Initiation date: Mar 2012 --> Jul 2012 N=162 --> 9

||||||||||  metformin / Generic mfg., drospirenone/ethinyl estradiol / Generic mfg.
New P3 trial:  Effects of Drospirenone-ethinylestradiol and/or Metformin on Cardiovascular Risk in Hyperinsulinemic Women With Polycystic Ovary Syndrome (clinicaltrials.gov) -  Apr 18, 2012
P3, N=99, Completed,  Sponsor: Catholic University of the Sacred Heart

|||||||||| Enrollment change, Head-to-Head: SoloPaP: Clinician-Collected Versus Patient-Collected Cervical Pap Smears (clinicaltrials.gov) - Apr 18, 2012
P=N/A, N=150, Completed, Sponsor: Mike O'Callaghan Federal Hospital
N=162 --> 9 N=100 --> 150

||||||||||  farletuzumab (MORAB-003) / Eisai
Enrollment change, Combination therapy:  An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer (clinicaltrials.gov) -  Apr 18, 2012
P3, N=417, Terminated,  Sponsor: Morphotek
N=100 --> 150 N=550 --> 417

||||||||||  triptorelin / Generic mfg.
New P4 trial:  ENDOFIV: The Effect of Pre-treatment With GnRH Analogues Prior in Vitro Fertilization in Patients With Endometriosis (clinicaltrials.gov) -  Apr 18, 2012
P4, N=272, Recruiting,  Sponsor: Instituto de Investigacion Sanitaria La Fe

|||||||||| Trial completion, Head-to-Head: SoloPaP: Clinician-Collected Versus Patient-Collected Cervical Pap Smears (clinicaltrials.gov) - Apr 18, 2012
P=N/A, N=150, Completed, Sponsor: Mike O'Callaghan Federal Hospital
N=550 --> 417 Active, not recruiting --> Completed

||||||||||  Ophena (ospemifene) / Shionogi
Enrollment change:  Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity (clinicaltrials.gov) -  Apr 17, 2012
P3, N=919, Completed,  Sponsor: Shionogi
Active, not recruiting --> Completed N=750 --> 919

||||||||||  Ophena (ospemifene) / Shionogi
Enrollment change:  A Clinical Study to Evaluate the Safety of Ospemifene (clinicaltrials.gov) -  Apr 17, 2012
P3, N=426, Completed,  Sponsor: Shionogi
N=750 --> 919 N=350 --> 426

|||||||||| Trial withdrawal, HEOR: Cost Utility Analysis in Recurrent Ovarian Cancer (clinicaltrials.gov) - Apr 17, 2012
P=N/A, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
N=350 --> 426 Recruiting --> Withdrawn

|||||||||| Enrollment change, HEOR: Cost Utility Analysis in Recurrent Ovarian Cancer (clinicaltrials.gov) - Apr 17, 2012
P=N/A, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Withdrawn N=43 --> 0

||||||||||  letrozole / Generic mfg.
Enrollment change, Metastases:  A Study of Letrozole in the Treatment of Endometrial Cancer (clinicaltrials.gov) -  Apr 17, 2012
P2, N=36, Completed,  Sponsor: Novartis Pharmaceuticals
N=43 --> 0 N=30 --> 36

||||||||||  Norditropin (somatropin) / Novo Nordisk
Trial completion:  Usability and Tolerability of the Norditropin NordiFlex (clinicaltrials.gov) -  Apr 17, 2012
P=N/A, N=79, Completed,  Sponsor: Novo Nordisk
N=30 --> 36 Active, not recruiting --> Completed

||||||||||  leuprolide acetate for depot suspension / Generic mfg.
Enrollment change:  GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients (clinicaltrials.gov) -  Apr 15, 2012
P2, N=60, Completed,  Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed N=75 --> 60

||||||||||  arsenic trioxide / Generic mfg.
Trial termination, Metastases:  Trisenox (clinicaltrials.gov) -  Apr 12, 2012
P2, N=5, Terminated,  Sponsor: UNC Lineberger Comprehensive Cancer Center
Recruiting --> Terminated; Accrual was very low. No subject had been enrolled in a year.